Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma-Reference-Cited by-同舟云学术

Phase I study of bortezomib plus ICE (BICE) for the treatment of relapsed/refractory Hodgkin lymphoma

Published:2011-04-26 Issue:2 Volume:154 Page:284-286
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:

Author:

Fanale Michelle,Fayad Luis,Pro Barbara,Samaniego Felipe,Liboon Mary Joy,Nunez Cesar,Horowitz Sandra,Anderlini Paolo,Popat Uday,Ji Yuan,Kwak Larry W.,Younes Anas

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2141.2011.08618.x/fullpdf

Reference9 articles.

1. A phase II study of bortezomib in relapsed Hodgkin lymphoma: preliminary results of CALGB 50206;Blum;Journal of Clinical Oncology Annual Meeting Abstracts,2006

2. The impact of pre- and post-transplantation positron emission tomography using 18-fluorodeoxyglucose on poor-prognosis lymphoma patients undergoing autologous stem cell transplantation;Filmont;Cancer,2007

3. Dose-finding in phase I clinical trials based on toxicity probability intervals;Ji;Clinical Trials,2007

4. A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model;Moskowitz;Blood,2001

5. Early FDG-PET assessment in combination with clinical risk scores determines prognosis in recurring lymphoma;Schot;Blood,2007

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas;Blood Advances;2018-12-20

2. Pharmacotherapeutic Management of Pediatric Lymphoma;Pediatric Drugs;2017-11-10

3. Advances in the pathophysiology and treatment of relapsed/refractory Hodgkin’s lymphoma with an emphasis on targeted therapies and transplantation strategies;Blood and Lymphatic Cancer: Targets and Therapy;2017-05

4. Approaches to modernize the combination drug development paradigm;Genome Medicine;2016-10-28

5. B-IGEV (bortezomib plus IGEV) versus IGEV before high-dose chemotherapy followed by autologous stem cell transplantation in relapsed or refractory Hodgkin lymphoma: a randomized, phase II trial of the Fondazione Italiana Linfomi (FIL);Leukemia & Lymphoma;2016-02-15